Mechanisms of hepatic microcirculatory disturbances induced by acute ethanol administration in rats, with special reference to alterations of sinusoidal endothelial fenestrae.
Elucidation of the hepatic hemodynamics in acute ethanol administration is an issue of clinical importance for better understanding of alcoholic liver diseases. The purpose of this study is to clarify the mechanism of hepatic microcirculatory disturbances after acute ethanol administration, especially regarding the effects of ethanol on alterations of sinusoidal endothelial fenestrae (SEF) and the involvement of endothelin-1 (ET-1) in the mechanism of portal hypertension induced by ethanol. Ethanol was administrated into the portal vein via the mesenteric vein branch of rats as a continuous infusion (4 and 8 mg/min of ethanol) for 60 min. Hepatic tissue blood flow measured with a laser Doppler blood flowmeter was found to be remarkably decreased with time, whereas portal pressure began to increase at 10 min and showed a significant increase by approximately 1.5 cm H2O at 60 min. Ethanol concentrations in blood at 60 min after 4 and 8 mg/min of ethanol infusion were 0.75 mg/ml and 1.77 mg/ml, respectively. At this point, scanning electron microscopy revealed significant decreases in number and diameter of SEF both in zone 1 and zone 3, with the increase in ethanol level. These findings suggested that decreases in number and diameter of SEF, whether primary or secondary, may lead to the impairment of the transport of plasma substances from sinusoids to hepatocytes in acute ethanol administration. Furthermore, the pretreatment of BQ-123 inhibited a decrease in hepatic tissue blood flow and an increase in portal pressure caused by ethanol, indicating that ET-1 may be involved in the mechanism of hepatic circulatory disturbances in acute ethanol administration.
Takashimizu
S
S
Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Watanabe
N
N
Nishizaki
Y
Y
Kawazoe
K
K
Matsuzaki
S
S
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001783:Blood Flow Velocity; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000502:physiology; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000648:ultrastructure; D000431:Ethanol / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D006975:Hypertension, Portal / Q000139:chemically induced; D007262:Infusions, Intravenous; D008099:Liver / Q000098:blood supply*; D008297:Male; D008642:Mesenteric Veins; D008854:Microscopy, Electron; D008855:Microscopy, Electron, Scanning; D010456:Peptides, Cyclic / Q000494:pharmacology; D011169:Portal Vein / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D044022:Receptor, Endothelin A; D014690:Venous Pressure
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D010456:Peptides, Cyclic; D044022:Receptor, Endothelin A; D000431:Ethanol; C072247:cyclo(Trp-Asp-Pro-Val-Leu)